Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: At all of the follow-ups, including the worst period (between four and ten weeks), the intervention group reported higher scores than the control group, suggesting in this RCT that adopting the person-centred-care concept was a promising way to improve function and wellbeing in patients with HNC.


Options:
A: Inclusion Criteria:

* Age ≥ 21
* Diagnosis of breast cancer, Stage III, IV, or Stage I or II with metastasis or recurrence
* Able to perform basic ADLs
* Undergoing chemotherapy and/or hormonal therapy for breast cancer
* Able to speak and understand English
* Have access to a telephone
* Able to hear normal conversation
* Cognitively oriented to time, place, and person (determined via nurse recruiter)

Exclusion Criteria:

* Diagnosis of major mental illness on the medical record and verified by the recruiter
* Residing in a nursing home
* Bedridden
* Currently receiving regular reflexology
* Diagnosis of symptoms of deep vein thrombosis or painful foot neuropathy, which will require medical approval
B: Inclusion Criteria:

* Diagnosis of primary glioma (WHO grades I-IV)
* Age ≥ 18
* Reference with diagnosis or treatment at Odense University Hospital
* Karnofsky performance score (KPS) ≥70
* Ability to understand Danish.

Exclusion Criteria:

* Pregnancy
* Known psychiatric diagnosis or substance abuse
* Heart problems excluding intense exercise (NYHA group III and IV)
* Pronounced impressive/expressive aphasia
C: Inclusion Criteria:

* Patients with either diagnosis of AML in first or second remission, in first untreated relapse (blast count in marrow \< 30%); ALL in first or second remission, in first untreated relapse (blast count in marrow \< 30%); CML in first chronic phase, in first accelerated phase (total blast and promyelocytes in marrow and or peripheral blood \< 30%) or MDS (excluding RAEB-t).
* Age between 18 and 55 years.
* ECOG performance status between 0,1 or 2.
* HLA-identical sibling donor.
* Written informed consent.

Exclusion Criteria:

* Serum creatinine more than 10% above the normal range for the centre.
* Left ventricular size and function abnormal.
* DLCO \< 50%.
* Bilirubin \> 2mg/dL (34.2 µmol/L).
* Splenectomised or splenic irradiation.
* Psychiatric, addictive, or any other disorder, which compromises ability to give truly informed consent for participation in this study.
* Currently receiving non-licensed drugs which may affect GVHD or engraftment.
* Pregnant or lactating women.
* Known sensitivity to E.coli derived products.
* HIV positive.
* Previously received BM/PBPC transplant.
D: Inclusion Criteria:

* Eligible for this study were patients diagnosed with HNC, older than 18 years and able to read and write Swedish and, in addition, suitable for outpatient treatment with chemo- and/or radiotherapy, either as primary treatment or in a postoperative setting.

Exclusion Criteria:

* Patients were excluded if they had a previous or concomitant malignancy or were diagnosed and treated for depression as stated in their medical record.
* In order to minimize the risk of bias, none of the patients were to be included if they were taking part in other research studies

Answer: D